Sanofi Pasteur SA

Sanofi Pasteur SA has been granted 24 US utility patents between 2015 and 2023, placing Sanofi Pasteur SA at rank #12,677 across all assignees tracked by PlainPatent. This portfolio spans 12 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.4 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Sanofi Pasteur SA is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 43.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 6 grants, compared with 18 in the 2015–2019 window — a -67% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Sanofi Pasteur SA's 18.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 12 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Sanofi Pasteur SA against peers pursuing similar technology classes.